PROVIDER PROFILE · NPI 1558507251

Rachel DamonRPA-C

PRACTICEDR. FAZELI & DR. BROUMAND LLCSee all providers at this practice →

Physician AssistantFayetteville, NYI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

1,699

Unique beneficiaries

—

Total services

3,035

Distinct HCPCS

Medicare payment

$90K

Peer benchmark

Total Medicare services vs. 8,690 Physician Assistant providers in NY — top quintile (cohort median 149).

PRESCRIBING · PART D · 2024

Total Rx claims

272

Beneficiaries

—

Total drug cost

$99K

Distinct drugs

Brand share

4.8%

Top prescribed drugs

Ketoconazole89 claims

Triamcinolone Acetonide62 claims

Clobetasol Propionate60 claims

Fluorouracil31 claims

Metronidazole17 claims

QUALITY · MIPS · 2024

Final MIPS score

93.6

Quality

100.0

Cost

78.5

Improvement activities

40.0

Promoting interop.

100.0

Payment adjustment

0.78%

Group

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$512

Payment records

By payment type

Food and Beverage$512

REFERRAL NETWORK

Where Rachel Damon's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 4 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
Cblpath, Inc Clinical Laboratory · Rye Brook, NY	75	138
Amin Fazeli Dermatology · Fayetteville, NY	28	43
Laboratory Alliance Of Central New York, Llc Clinical Laboratory · Liverpool, NY	18	48
ST JOSEPHS HOSPITAL HEALTH CENTER	12	14

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history